Lantheus Holdings Inc (LNTH, Financial) has recently caught the attention of investors with its notable stock performance. The company's market capitalization stands at a robust $4.38 billion, with the current stock price at $63.9. Over the past week, the stock has experienced a 2.71% gain, and looking at the past three months, there has been an impressive 11.24% gain. According to GF Value, the stock is currently significantly undervalued with a GF Value of $92.28, up from the past GF Value of $87.97. This suggests that the stock may have room to grow, maintaining its status as significantly undervalued both currently and in the past valuation.
Introduction to Lantheus Holdings Inc
Lantheus Holdings Inc, operating within the drug manufacturers industry, is a company that specializes in the development of diagnostic products. These products are categorized into Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships. The company's Precision Diagnostic products are designed to assist healthcare professionals in the detection and monitoring of diseases, particularly in cardiology. Their Radiopharmaceutical Oncology segment provides diagnostics and therapeutics for the management of cancer. Additionally, Lantheus Holdings Inc's Strategic Partnerships aim to enable precision medicine through various platforms, including the licensing of RELISTOR to Bausch Health Companies, Inc.
Assessing Profitability
Lantheus Holdings Inc boasts a strong Profitability Rank of 8/10, indicating a high likelihood of the company maintaining its profitability. The company's operating margin is an impressive 28.13%, which is better than 94.31% of 1020 companies in the industry. Its Return on Equity (ROE) is at a staggering 55.18%, surpassing 97.8% of its peers. The Return on Assets (ROA) stands at 22.74%, and the Return on Invested Capital (ROIC) is at 36.47%, both metrics outperforming the majority of competitors. Over the past decade, Lantheus Holdings has been profitable for six years, showcasing its financial stability within the drug manufacturing sector.
Growth Trajectory of Lantheus Holdings
The company's Growth Rank is an exceptional 9/10, reflecting its strong revenue and profitability expansion. Lantheus Holdings has achieved a 43.30% 3-Year Revenue Growth Rate per Share, outperforming 93.28% of 923 companies in the industry. Its 5-Year Revenue Growth Rate per Share is 15.50%, which is better than 80.74% of 815 companies. Looking ahead, the Total Revenue Growth Rate (Future 3Y To 5Y Est) is projected at 10.78%, indicating a healthy growth trajectory for the company. This growth rate is more favorable than 71.29% of 202 companies, suggesting that Lantheus Holdings is well-positioned for future expansion.
Notable Shareholders in Lantheus Holdings
Among the notable holders of Lantheus Holdings stock, Private Capital (Trades, Portfolio) leads with 556,771 shares, representing a 0.81% share percentage. Following closely is renowned investor Ken Fisher (Trades, Portfolio), holding 158,504 shares, which equates to a 0.23% stake in the company. Steven Cohen (Trades, Portfolio) also has a significant investment with 123,638 shares, accounting for 0.18% of the company's shares. These prominent investors' involvement underscores the confidence in Lantheus Holdings' potential and strategic direction.
Competitive Landscape
When comparing Lantheus Holdings to its competitors, it stands strong in the market. Elanco Animal Health Inc (ELAN, Financial) has a market cap of $6.59 billion, while Alkermes PLC (ALKS, Financial) is valued at $4.05 billion. Intra-Cellular Therapies Inc (ITCI, Financial) has a market cap of $6.98 billion. These companies, along with Lantheus Holdings, form a competitive landscape within the drug manufacturing industry, each with its unique strengths and market positions.
Conclusion
In summary, Lantheus Holdings Inc's stock performance has been remarkable, with significant gains over the past quarter. The company's high profitability and growth ranks, coupled with its strong operating margin, ROE, ROA, and ROIC, paint a picture of a robust company with a solid financial foundation. The projected revenue growth rates further indicate a promising future. With the backing of notable investors and a competitive standing in the drug manufacturing industry, Lantheus Holdings Inc is a company that value investors should watch closely.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
